Paradigm Biopharma (ASX: PAR)


Paradigm Biopharma (ASX: PAR) is a biopharmaceutical company focused on repurposing the drug ‘pentosan polysulphate sodium’ (PPS) for the treatment of inflammation. www.paradigmbiopharma.com

Paradigm Biopharmaceuticals ASX PAR Zilosul COVID-19 knee osteoarthritis

Paradigm doses all trial patients with Zilosul while dodging COVID-19 impact

An experimental treatment for knee osteoarthritis developed by Paradigm Biopharmaceuticals (ASX: PAR), Zilosul, has now been dosed...
Paradigm Biopharmaceuticals NFL Mitch Marrow iPPs Zilosul FDA ASX PAR

Paradigm Biopharmaceuticals announces first Zilosul patient under FDA approved program

Paradigm Biopharmaceuticals (ASX: PAR) has declared that the first patient has been dosed under the FDA-approved expanded...
Paradigm Biopharmaceuticals osteoarthritis ASX PAR clinical development regulatory milestones Zilosul

Paradigm Biopharmaceuticals gears up for busy year of clinical trials and regulatory submissions in...

With progress to secure regulatory approvals underway for its flagship Zilosul treatment, Paradigm Biopharmaceuticals (ASX: PAR) is...
Paradigm Biopharmaceuticals ASX PAR regulatory progress iPPS Zilosul

Regulatory progress means Paradigm Biopharmaceuticals will treat ex-NFL players with Zilosul later this year

Paradigm Biopharmaceuticals (ASX: PAR) has been given the go-ahead by US regulators to treat 10 former NFL...
Paradigm Biopharmaceuticals ASX PAR pentosan polysulfate sodium Zilosul PLOs One peer reviewed

Paradigm Biopharmaceuticals looks to alleviate opiate crisis following ‘ground-breaking discovery

Paradigm Biopharmaceuticals (ASX: PAR) claims it has made a “ground-breaking discovery” as part of its ongoing development...
Paradigm Biopharma ASX PAR receives FDA clearance investigational new osteoarthritis drug pentosan polysulfate sodium

Paradigm Biopharma receives FDA clearance for investigational new osteoarthritis drug

Medical company Paradigm Biopharmaceuticals (ASX: PAR) has received clearance from the US Food and Drug Administration for...
Paradigm Biopharmaceuticals PAR ASX Zilosul cartilage knee osteoarthritis iPPS

Paradigm Biopharma’s knee osteoarthritis trial shows injectable drug can slow cartilage degradation

Paradigm Biopharmaceuticals (ASX: PAR) has reported a breakthrough in its phase 2 clinical trial of the injectable...
Paradigm Biopharmaceuticals ASX PAR US investigational new drug

Paradigm submits first investigational new drug application with US FDA

Medical company Paradigm Biopharmaceuticals (ASX: PAR) has set the stage for a speedy entry into the US...
Paradigm Biopharmaceuticals ASX PAR Ross River virus phase 2A clinical trial success

Paradigm Biopharmaceuticals’ iPPS reduces Ross River virus joint pain

Paradigm Biopharmaceuticals (ASX: PAR) has reported reduced disease symptoms during a phase 2a trial using its injectable...
Paradigm Biopharmaceuticals ASX PAR pain reduction knee osteoarthritis iPPS

Real world trial of Paradigm Biopharma’s injectable drug reduces osteoarthritic pain by over 50%

A real-world trial using Paradigm Biopharmaceuticals’ (ASX: PAR) injectable pentosan polysulfate (iPPS) treatment has found the drug...
Paradigm Biopharmaceuticals ASX PAR bone marrow lesions hip knee cap ankle iPPS

Paradigm Biopharmaceuticals’ iPPS drug reduces bone marrow lesions in hip, knee caps and ankles

As it advances its injectable Pentosan Polysulfate (iPPS) drug towards commercialisation, Paradigm Biopharmaceuticals (ASX: PAR) has noted...
Paradigm Biopharma ASX PAR phase 2b secondary endpoints pentosan polysulfate sodium

Paradigm Biopharma’s knee osteoarthritis trial meets secondary endpoints, launches capital raise

Paradigm Biopharmaceuticals (ASX: PAR) has announced trial patients being treated with its injectable pentosan polysulfate sodium (iPPS)...
Paradigm Biopharmaceuticals ASX PAR IND applicaton mucopolysaccharidosis MPS disease

International symposium sets scene for Paradigm Biopharmaceuticals’ MPS trial

Paradigm Biopharmaceuticals (ASX: PAR) has set its sights on applying to the US Food and Drug Administration...
Paradigm Biopharmaceuticals ASX PAR primary endpoints Phase 2b knee osteoarthritis trial

Paradigm Biopharmaceuticals meets primary endpoints in Phase 2b knee osteoarthritis trial

Paradigm Biopharmaceuticals (ASX: PAR) has confirmed the potential of its injectable pentosan polysulfate sodium (iPPS) drug to...
Paradigm Biopharmaceuticals PAR ASX knee pain reduction osteoarthritis

Paradigm Biopharmaceuticals reasserts osteoarthritis pain reduction results

Biotechnology company Paradigm Biopharmaceuticals (ASX: PAR) has reasserted its previously published figures relating to pain reduction resulting from...
Paradigm Biopharmaceuticals ASX PAR Pentosan Polysulfate Sodium Icahn School of Medicine at Mount Sinai

Paradigm Biopharmaceuticals to deploy iPPS to treat rare joint disease

Biotechnology company Paradigm Biopharmaceuticals (ASX: PAR) is continuing to expand the gamut of applications for its proprietary Pentosan Polysulfate...
Paradigm Pharmaceuticals ASX PAR Australian Government research and development tax refund

Australian Government numbs capital expenditure pain for Paradigm Biopharmaceuticals

Biotechnology company Paradigm Biopharmaceuticals (ASX: PAR) has received a further boost in its mission to bring a potentially...
Paradigm Biopharma injectable osteoarthritis drug trial reduction chronic pain knee OA

Paradigm’s injectable osteoarthritis drug trial shows major reduction in chronic pain

Australian biotech company Paradigm Pharmaceuticals (ASX: PAR) has reported an average 51.2% reduction in chronic knee pain...
Paradigm Biopharmaceuticals ASX PAR Pro Players Elite Network NFL athletes

Paradigm Biopharmaceuticals looks to touchdown its osteoarthritis drug in the United States

Paradigm Biopharmaceuticals (ASX: PAR) has struck a strategic partnership with the Pro Players’ Elite Network (PPEN), a...
Paradigm Biopharmaceuticals ASX PAR chronic pain reduction osteoarthritis

Paradigm Biopharmaceuticals looks to scale summit of chronic pain reduction

Biotech company Paradigm Biopharmaceuticals (ASX: PAR) continues to make progress on its mission of developing a radical shift...
Paradigm Biopharma ASX PAR complete recruitment Ross River virus clinical study trial

Paradigm Biopharma weathers seasonal change to complete recruitment for Ross River virus study

Paradigm Biopharmaceuticals (ASX: PAR) has completed the recruitment stage of its phase 2a clinical trial in participants...